CRISPR Therapeutics
CRSP
CRSP
155 hedge funds and large institutions have $631M invested in CRISPR Therapeutics in 2018 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 41 increasing their positions, 44 reducing their positions, and 52 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
35% less call options, than puts
Call options by funds: $11.4M | Put options by funds: $17.5M
37% less capital invested
Capital invested by funds: $1.01B → $631M (-$377M)
42% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 52
Holders
155
Holding in Top 10
4
Calls
$11.4M
Puts
$17.5M
Top Buyers
| 1 | +$16.6M | |
| 2 | +$11.8M | |
| 3 | +$6.61M | |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$5.11M |
| 5 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$5.1M |
Top Sellers
| 1 | -$24M | |
| 2 | -$22M | |
| 3 | -$9.76M | |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$8.32M |
| 5 |
JPMorgan Chase & Co
New York
|
-$7.68M |